Showing results (71-80 of 79) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Veterinary Microbiology|September 1, 1996
Validation of random amplified polymorphic DNA assays by ribotyping as tools for epidemiological surveys of Pasteurella from animalsE Chaslus-Dancla, M C Lesage-Decauses, S Leroy-Sétrin, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|January 1, 1990
Comparative effects of some 3-amino 4,6-diarylpyridazines on the biosynthesis in vitro of TXA2 and PGI2- and on the TXA2- and PGI2-synthesizing activities of cardiac tissueH C Pham, V Dossou-Gbete, R Kaiser, et al.Veterinary Journal (London, England : 1997)|September 13, 2005
Infectious agents associated with epizootic rabbit enteropathy: isolation and attempts to reproduce the syndromeD Marlier, R Dewrée, C Lassence, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|September 1, 1994
Thromboxane A2 biosynthesis inhibitors: synthesis and evaluation of pyrazolotriazinyl alkanoic acidsB Lasserre, S Mavel, P Coudert, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|June 1, 1997
Pharmacophore requirements in new series of pyridazinyl alkanoic acids, N-[(pyridazin-2-yl) alkyl] succinyl and glutaryl amides, inhibitors of thromboxane A2 biosynthesisS Moreau, P Coudert, B Lasserre, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplificationLaurent Arnould, Patrick Arveux, Jerome Couturier, et al.Journal of the National Cancer Institute|September 5, 1990
Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell linesT L McLemore, C L Litterst, B P Coudert, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2005
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trialB P Coudert, L Arnould, L Moreau, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2007
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trialBruno P Coudert, Remy Largillier, Laurent Arnould, et al.Pageof 8